Orphazyme halves board of directors – chair not up for reelection

As the firm concludes operational activities following a sale of the business to Kempharm, Oprhazyme has halved its board of directors. The firm’s chair will also step down following its AGM in June.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

Three is the magic number after biotech firm Orphazyme has halved its board of directors, which used to count six people, the firm reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading